Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable or non-dilatable lesions, as it allows for calcium ablation or fracturing. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

The ECLIPSE study, a randomized trial, compared orbital atherectomy (OA) with balloon angioplasty (including cutting and scoring balloons) for the treatment of severely calcified lesions before drug-eluting stent (DES) implantation.

This study included patients with chronic and acute coronary syndromes (without ST elevation) and de novo lesions with severe calcification, as determined by angiography or intravascular ultrasound (IVUS)/optical coherence tomography (OCT), where plaque preparation was feasible with either therapy. 

A total of 2005 patients were enrolled across 104 US centers. Randomization was 1:1. The primary endpoints were (1) imaging analysis assessing minimal stent area (MSA) post-PCI, and (2) target vessel failure (TVF) at one year.

The average participant age was 69.9 years; 73.6% of subjects were men, and 23% had chronic kidney disease.

Read also: TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE.

In terms of the procedure, 47.6% of the orbital atherectomy group was treated via transfemoral access, 4.6% required a temporary pacemaker, 21.4% needed an extension catheter, and 42% used an OTW microcatheter or balloon. Intravascular imaging was used in 62.1% of procedures (40.3% of cases used OCT and 25.6%, IVUS).

In an analysis of the complications, there were low rates of no-reflow (0.3% vs 0.1%), type C-F dissections (6.9% vs 6.3%), and perforations (1.8% vs 1%, mostly Ellis type III). The incidence of slow flow was higher in the OA group (1.4% vs 0.4%; p=0.03). 

MSA in the most calcified region was 7.44 vs 7.05, a non-significant difference (-0.26 mm²; p=0.08). Regarding TVF at 1 year, orbital atherectomy showed an incidence of 11.5% vs 10.0% (hazard ratio [HR] 1.16; 95% confidence interval [CI] 0.87-1.54; p=0.28). 

Read also: TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting.

Regarding secondary endpoints, the OA group had higher cardiovascular mortality (p=0.005) and both groups had a similar stent thrombosis rate (0.7% vs 0.3%).

The authors concluded that routine use of orbital atherectomy did not improve MSA or reduce TVF compared with balloon PCI.

Presented by Ajay J Kirtane in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...